Cytogen shuts down Cellcor division

Article

After months of unsuccessful searching for a buyout candidate for its Cellcor subsidiary, Cytogen closed the division on Sept. 18. Cytogen bought Cellcor in 1995 in hopes of bringing to market that company’s autolymphocyte therapy (ALT) cancer

After months of unsuccessful searching for a buyout candidate for its Cellcor subsidiary, Cytogen closed the division on Sept. 18. Cytogen bought Cellcor in 1995 in hopes of bringing to market that company’s autolymphocyte therapy (ALT) cancer therapy technology in development. That effort apparently didn’t go as planned, however, and Cytogen early this spring put Cellcor on the block. Cytogen reported in July that unless the company was able to find a buyer by September, Cellcor’s operations would cease.

Shutting Cellcor down is part of the Princeton, NJ, company’s attempt to reduce operating expenses and focus its corporate efforts on marketing radiopharmaceutical agents OncoScint, ProstaScint, and Quadramet. Cytogen tightened its belt further last month when it sold its interest in its subsidiary Targon back to the original owner, pharmaceutical firm Elan of Dublin, Ireland, after only two years of ownership. In addition to closing Cellcor and divesting its Targon interest, Cytogen expects to cut its workforce by 30%, according to Joseph Reiser, president and CEO. Cytogen anticipates a special charge in the third quarter of 1998 for severance and other closure-related expenses.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.